Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VLA1601

Vaccine · Immune activation · developed by Valneva Austria GmbH

Phase 1 Most advanced trial (none active)

VALN Developer

1 Registered trials

What is VLA1601?

VLA1601 is a vaccine studied for the prevention of Zika virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06334393	Phase 1	Zika	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ZikaZika Virus Infection

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1553 Phase 3

Sources

ClinicalTrials.gov NCT06334393

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind VLA1601

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z